{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-000614","form_type":"8-K/A","ticker":"ACH","cik":"0000075252","company_name":"ACCENDRA HEALTH INC/VA/","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.644189+00:00","generated_at":"2026-05-16T11:45:58.601008+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Accendra Health closes P&HS sale for $375M cash; pro forma revenue falls to $2.68B","bullets":["Sold P&HS business for $375M cash on Dec 31, 2025; proceeds used to repay $280M current debt.","Pro forma 2024 revenue $2.68B (vs $10.7B reported); net loss pro forma $366.5M vs $362.7M.","Pro forma diluted EPS: 2024 -$4.78, 2023 -$0.15, 2022 -$0.72.","Amended Receivables Sale Program: sold $94M eligible receivables, removed $160M intercompany payable.","Retained a 5% equity interest in buyer with potential for up to $200M of priority distributions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-000614","json":"https://secwatch.observer/filing/0001104659-26-000614.json","markdown":"https://secwatch.observer/filing/0001104659-26-000614.md","text":"https://secwatch.observer/filing/0001104659-26-000614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/75252/000110465926000614/0001104659-26-000614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/75252/000110465926000614/omi-20251224x8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:45:58.601008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}